Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Ann Diagn Pathol ; 70: 152287, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38479198

RESUMO

While eosinophilic esophagitis (EOE) is defined by histologic presence of eosinophils, a few studies have established the presence of mast cells in EOE and even shown their correlation with symptom persistence despite resolution of eosinophils. Expression of aberrant mast cell markers CD25 and CD2 have not been studied in EOE. This study quantifies the number of hotspot cells per high power field expressing CKIT/CD117, tryptase, CD25, CD2 and CD3 by immunohistochemical stains in endoscopic esophageal biopsies of the following three cohorts: (1) established and histologically confirmed EOE, (2) suspected EOE with biopsies negative for eosinophils, and (3) no history of or suspicion for EOE with histologically unremarkable biopsies. In this study, mast cells were highlighted by CKIT and tryptase in EOE, and not seen in other clinically mimicking cases. There were also significantly higher densities of CD25 and pan-T-cell marker staining in EOE cases. These findings suggest an inflammatory cellular milieu in EOE, beyond just eosinophils, that can be demonstrated by immunohistochemistry, and that invite further study into the role that these cells may play in EOE.


Assuntos
Biomarcadores , Esofagite Eosinofílica , Eosinófilos , Subunidade alfa de Receptor de Interleucina-2 , Mastócitos , Linfócitos T , Humanos , Esofagite Eosinofílica/patologia , Esofagite Eosinofílica/metabolismo , Esofagite Eosinofílica/diagnóstico , Mastócitos/patologia , Mastócitos/metabolismo , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Masculino , Biomarcadores/metabolismo , Feminino , Linfócitos T/patologia , Linfócitos T/metabolismo , Eosinófilos/patologia , Eosinófilos/metabolismo , Adulto , Imuno-Histoquímica/métodos , Biópsia , Pessoa de Meia-Idade , Criança , Adolescente , Triptases/metabolismo , Adulto Jovem , Esôfago/patologia , Esôfago/metabolismo , Pré-Escolar
2.
Cells ; 13(10)2024 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-38786020

RESUMO

A heterogenous population of inflammatory elements, other immune and nonimmune cells and cancer-associated fibroblasts (CAFs) are evident in solid malignancies where they coexist with the growing tumor mass. In highly desmoplastic malignancies, CAFs are the prominent mesenchymal cell type in the tumor microenvironment (TME), where their presence and abundance signal a poor prognosis. CAFs play a major role in the progression of various cancers by remodeling the supporting stroma into a dense, fibrotic matrix while secreting factors that promote the maintenance of cancer stem-like characteristics, tumor cell survival, aggressive growth and metastasis and reduced sensitivity to chemotherapeutics. Tumors with high stromal fibrotic signatures are more likely to be associated with drug resistance and eventual relapse. Identifying the molecular underpinnings for such multidirectional crosstalk among the various normal and neoplastic cell types in the TME may provide new targets and novel opportunities for therapeutic intervention. This review highlights recent concepts regarding the complexity of CAF biology in cholangiocarcinoma, a highly desmoplastic cancer. The discussion focuses on CAF heterogeneity, functionality in drug resistance, contributions to a progressively fibrotic tumor stroma, the involved signaling pathways and the participating genes.


Assuntos
Fibroblastos Associados a Câncer , Colangiocarcinoma , Progressão da Doença , Microambiente Tumoral , Humanos , Colangiocarcinoma/patologia , Colangiocarcinoma/genética , Colangiocarcinoma/tratamento farmacológico , Colangiocarcinoma/metabolismo , Fibroblastos Associados a Câncer/metabolismo , Fibroblastos Associados a Câncer/patologia , Neoplasias dos Ductos Biliares/patologia , Neoplasias dos Ductos Biliares/genética , Neoplasias dos Ductos Biliares/tratamento farmacológico , Neoplasias dos Ductos Biliares/metabolismo , Animais , Transdução de Sinais , Resistencia a Medicamentos Antineoplásicos/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA